Journal of Medicinal Chemistry · 2003 · 78 citations · 16 references
MedicineMedicinal ChemistryPharmacologyClinical PharmacologyDrug DiscoveryDrug MetabolismCytochrome P450 EnzymesCytochrome P450 InteractionsCytochrome P450-mediated MetabolismDrug-metabolizing EnzymesEnzyme InhibitionCytochrome EnzymesCytochrome P450 Drug MetabolismCytochrome P450 Enzyme ActivityCytochrome P450 Enzyme InhibitionImidazole ChemistryIsoxazole ChemistryMedicinal Chemistry ApplicationsSolubility
In a previous paper, we reported the N-hydroxyformamidine derivative HET0016 as a potent and selective 20-HETE synthase inhibitor. Despite its attraction as a potential therapeutic agent for cerebral diseases, the preparation of an injectable formulation of HET0016 was limited by its poor solubility under neutral conditions and instability under acidic conditions. The instability of HET0016 in acidic conditions is due to the N-hydroxyformamidine moiety, which is considered to be essential for the potent and selective activity seen in our previous study. The activity was maintained when the N-hydroxyformamidine moiety was replaced by an imidazole ring (3a; IC(50) = 5.7 +/- 1.0 nM), but this was associated with a loss of selectivity for cytochrome p450s (CYPs). However, other azole derivatives such as isoxazole derivative 23 (IC(50) value 38 +/- 10 nM) and pyrazole derivative 24 (IC(50) value 23 +/- 12 nM) showed potent and selective activities with improved stability.
16
Production of 20-HETE and Its Role in Autoregulation of Cerebral Blood Flow
Debebe Gebremedhin, Andrew R. Lange, T. F. Lowry et al. · Circulation Research · 2000 · 317 citations
Medicine, Pharmacology, Physiology +16
HET0016, a potent and selective inhibitor of 20‐HETE synthesizing enzyme
Noriyuki Miyata, Kazuo Taniguchi, Takayuki Seki et al. · British Journal of Pharmacology · 2001 · 197 citations · Full text
Medicine, Biochemistry, Pharmacology +16